Oruka Therapeutics, Inc. Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

ORKA

Pozycja w akcjach #3282
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Cena akcji
$80.79
Kapitalizacja rynkowa
$5.35B
Zmiana (1 dzień)
1.08%
Zmiana (1 rok)
203.13%
Kraj
US
Handel Oruka Therapeutics, Inc. (ORKA)

Kategoria

Healthcare
Wskaźnik P/S dla Oruka Therapeutics, Inc. (ORKA)
Wskaźnik P/S na dzień October 2026 TTM: 0.00
Według najnowszych raportów finansowych i ceny akcji Oruka Therapeutics, Inc., obecny wskaźnik P/S (TTM) wynosi 0.00. Na koniec 2024 wynosił 0.00.
Historia wskaźnika P/S dla Oruka Therapeutics, Inc. od 2005 do 2026
Wskaźnik P/S na koniec każdego roku
Rok Wskaźnik P/S Zmień
2026 (TTM) 0.00 0.00%
2025 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
2011 0.00 0.00%
2010 0.00 0.00%
2009 0.00 0.00%
2008 0.00 -100.00%
2007 2.08 -96.07%
2006 52.93 -91.38%
2005 614.26 0.00%
Wskaźnik P/S dla podobnych firm lub konkurentów
Firma Wskaźnik P/S Różnica wskaźnika P/S Kraj
10.72 -
US
41.70 -
US
4.19 -
AU
5.80 -
BE
10.44 -
NL